The FDA has approved Brooklyn-based biotechnology company Cresilon’s novel hemostatic gel, Traumagel, which is intended to stop serious bleeding quickly. With the intention of serving the requirements of the American military, emergency medical services (EMS), government health agencies, and medical professionals, this plant-based gel is the first hemostatic medical device to receive FDA approval for exterior use.
Anyone suffering from catastrophic injuries where significant blood loss could kill them in a matter of minutes is intended to use Traumagel. It tackles the drawbacks of the bandages, gauze, and hemostatic agents that are now available, which frequently call for significant preparation or specialized knowledge to use. Because Cresilon’s Traumagel is pre-filled in syringes, easy to use, and doesn’t require any preparation, it is quite effective at stopping bleeding quickly from a variety of wounds. The CEO and co-founder of Cresilon, Joe Landolina, emphasizes that the technology is a “game-changer” in emergency medicine, able to save lives by promptly stopping life-threatening hemorrhages.
This breakthrough is much needed, particularly for military applications where wounds must be treated right away. Traumagel offers a much-needed answer for medical professionals and warriors alike, allowing them to control serious bleeding in emergency situations or on the battlefield with its quick and easy administration.
Cresilon plans to launch Traumagel in the U.S. by late 2024. Notably, the company has previously received FDA clearance for a similar hemostatic gel for minor wounds. Additionally, Cresilon manufactures Vetigel, a product for animals that works similarly to stop both internal and external bleeding. Both products are biocompatible and require no preparation, reinforcing Cresilon’s position as a leader in innovative hemostatic technologies.